Large Cap - Spark Newswire

1 minute read

FDA Pushes Merck’s Pneumococcal Vaccine Decision Date Into July For Expanded Use In Kids

Today, 10:25 PM

The FDA has extended the Prescription Drug User Fee Act (PDUFA) date of the supplemental marketing application for Merck & Co Inc's (NYSE: MRK) pneumococcal 15-valent conjugate vaccine

MRK

1 minute read

EMA’s Advisory Group Backs Approval For Merck’s Keytruda In Various Cancer Settings

By Vandana Singh

Today, 10:25 PM

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Merck & Co Inc (NYSE: MRK) for

MRK

1 minute read

FDA Pushes Bristol Myers’ Reblozyl Decision Date In Non-Transfusion Dependent Beta Thalassemia

By Vandana Singh

Today, 10:25 PM

The

BMY

2 minute read

Jim Cramer Thinks ‘The Bear Market Is Finished’: Top Picks Include Nvidia And These 2 FAANGs

By Adam Eckert

Today, 10:25 PM

Many of the mega-cap technology names have snapped back off the lows since entering correction territory. Jim Cramer on Thursday provided an interpretation of the recent strength in the tech-heavy Nasdaq. "I look at the Nasdaq and I think maybe the bear market is finished," Cramer said on CNBC's "Squawk On The Street."

1 minute read

FDA Approves Novartis’ Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer

By Vandana Singh

Today, 10:25 PM

The FDA approved Novartis AG’s (NYSE:NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with a type of advanced prostate…

NVS

1 minute read

Bristol Myers Squibb Embarks Oncology Pact With Volastra Therapeutics

By Vandana Singh

Today, 10:25 PM

Bristol Myers Squibb Co (NYSE: BMY) is pairing with New York-based biotech Volastra Therapeutics.

BMY

2 minute read

Barron’s Latest Picks And Pans: Nvidia, Wayfair, Moderna, Pfizer, Palo Alto Networks

By Michael Cohen

Today, 10:25 PM

This weekend's Barron's cover story says the implications of fast-rising costs of essentials go beyond the obvious threats to consumers’ standards of living and ability to drive broad economic growth.

MRNA

1 minute read

Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients

By Vandana Singh

Today, 10:25 PM

Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).

AZN

1 minute read

Novartis’s Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study

By Vandana Singh

Today, 10:25 PM

Novartis AG (NYSE:NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for…

NVS

1 minute read

Merck’s Keytruda Shows Improved Metastasis-Free Survival In Melanoma Patients

By Vandana Singh

Today, 10:25 PM

Merck & Co Inc (NYSE: MRK) announced data from Phase 3 KEYNOTE-716 trial of Keytruda (pembrolizumab) as adjuvant treatment for patients with resected stage IIB and IIC melanoma.

MRK